Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

BlueRock Therapeutics

- PMLiVE

UK drug repurposing study identifies several potential dementia treatments

An estimated 982,000 people in the UK are currently living with the neurodegenerative disease

Bayer symbol

Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

- PMLiVE

Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies

The neurodegenerative disease affects approximately 30,000 people in the US

- PMLiVE

GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

- PMLiVE

Researchers develop new approach to target cells affected by motor neurone disease

The technique could lead to safer and more effective gene therapies for the neurodegenerative disease

Bayer symbol

Bayer presents positive results for Kerendia in late-stage heart failure study

Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

Bayer symbol

Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

The companies will advance small molecule therapeutics against a new class of targets for cancer

- PMLiVE

Mayo Clinic explores AI and brain waves for neurodegenerative disease diagnosis

The team is using AI to assist in analysing routine EEGs for early identification of brain disorders

Bayer symbol

Bayer shares promising results for Kerendia in phase 3 heart failure study

Approximately 55% of heart failure patients have an LVEF of at least 40%

- PMLiVE

Roche’s Genentech and Sangamo enter neurodegenerative disease partnership worth over $1.9bn

According to WHO, neurological conditions are now the leading cause of ill health and disability worldwide

- PMLiVE

NHS figures reveal record number of people in England being diagnosed with dementia

Around a third of people living with dementia in England have not received a diagnosis

Bayer symbol

Bayer/Orion’s darolutamide combination shows promise in phase 3 prostate cancer trial

The results from the study will support regulatory applications for wider use of the drug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links